MIRA Pharmaceuticals Shares Surge 40% After Ketamir-2 Excels in Pain Management Trials
MIRA Pharmaceuticals (MIRA, Financial) shares soared by 40% after the company achieved a significant breakthrough in ...
Sacramento Bee11d
MIRA Pharmaceuticals Announces Ketamir-2 Outperforms Current FDA-Approved Neuropathic Pain Treatments, Gabapentin and Pregabalin, in Preclinical Study
Expanding Ketamir-2's Potential Beyond Neuropathic Pain: MIRA is actively preparing to launch preclinical ... This press ...
MIRA Pharmaceuticals' Ketamir-2 Shows 60% Greater Efficacy Than FDA-Approved Gabapentin in Reversing Chemotherapy-Induced Neuropathic Pain
Promising Preclinical Results Position Ketamir-2 as a Potential Breakthrough Therapy That Surpasses Current Treatments, With Results to Be ...
greenmarketreport9d
MIRA says ketamine-based drug beats current pain treatments in study
The firm says it could offer an alternative to existing treatments while sidestepping addiction concerns that have plagued ...
Becker's ASC10d
Study finds racial disparities in post-op pain management: 6 things to know
1. The authors of the retrospective study compared the postsurgical pain management given to 2,460 white patients and 482 Black patients in intensive care during the first 24 hours after "complex, ...
MIRA Pharmaceuticals' Formulated Shows Greater Efficacy Than FDA-Approved Drug For Chemo-Induced Neuropathic Pain
MIRA Pharmaceuticals, Inc. (NASDAQ:MIRA) stock is trading higher on Monday after the company released new preclinical ...
Kansas City Star11d
MIRA Pharmaceuticals Announces Ketamir-2 Outperforms Current FDA-Approved Neuropathic Pain Treatments, Gabapentin and Pregabalin, in Preclinical Study
Expanding Ketamir-2's Potential Beyond Neuropathic Pain: MIRA is actively preparing ... of MIRA Pharmaceuticals' (or the "Company") management related thereto contain "forward-looking statements ...